Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

- PMLiVE

Lundbeck’s desmoteplase flunks phase III stroke trial

No better than placebo at improving disability symptoms

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

- PMLiVE

Niche-busting cancer immunotherapies

Targeted oncology treatments are a reason for hope

- PMLiVE

Merck KGaA furthers antibody ambitions in cancer

Signs deal with Mersana to develop antibody-drug conjugates

- PMLiVE

Pfizer turns to cancer immunotherapies

Signs deal with French company Cellectis

- PMLiVE

Lilly’s Cyramza disappoints in liver cancer

Fails to improve overall survival by significant margin

- PMLiVE

SMC: Celgene’s Abraxane ‘too expensive’ for Scotland

But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta

- PMLiVE

ASCO: AstraZeneca shows off cancer immunotherapy

MEDI4736 could rival Merck & Co’s anti-PD1 inhibitor pembrolizumab

- PMLiVE

ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab

- PMLiVE

US cancer ads come under fire

Study concludes that cancer advertisements tug at the heartstrings without providing sufficient information

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links